You don't need two-hour workouts
When patients stayed on treatment for the full duration, that number climbed to 16.6%, essentially matching the weight loss performance of injectable WEGOVY 2.4 mg
44 The 52-week data from 966 patients with MASH and F1B, F2, or F3 fibrosis in the MAESTRO-NASH trial revealed significant effects of resmetirom on MASH resolution, fibrosis improvement, and LDL cholesterol reduction (NCT03900429), 77 forming the basis for potential FDA approval of resmetirom for MASH treatment
Tested Before Release Every batch verified by an independent US analytical lab before release
Check your prescription coverage If you have insurance, check the drug formulary (list of covered drugs) or contact your insurance provider to verify if Wegovy is covered for your prescribed diagnosis
The antioxidant is a new ingredient in the hyperpigmentation-clearing space and is being touted as 10 times more effective than vitamin C